Cutaneous Squamous cell Carcinoma - Competitive Landscape, Market Insights, Epidemiology and Market Forecast - 2025

  • ID: 4330870
  • Drug Pipelines
  • 131 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 3
‘Cutaneous Squamous Cell Carcinoma (cSCC) - Competitive Landscape, Market Insights, Epidemiology and Market Forecast - 2025’ report provides provides the comprehensive insights on the competitive landscape and market of Cutaneous Squamous Cell Carcinoma (cSCC).
  • The report covers the overview of the Cutaneous Squamous Cell Carcinoma along with the epidemiology and the market scenario in the 7MM - United States, EU5 (Germany, France, Spain Italy , United Kingdom) and Japan. The Report provides a comprehensive review of the unmet medical needs of the disease, market trends, drivers and market barriers.
  • The competitive landscape of the report covers both pipeline and marketed portfolio of the indication. Cutaneous Squamous Cell Carcinoma pipeline provides information on the therapeutic drugs in development and comparative analysis at various stages covering clinical and pre-clinical & discovery stages, therapeutics assessment by Monotherapy/Combination products and Molecule Type drug analysis. It also provides in-depth analysis on the Phase III profile covering clinical trial studies, recent developments and SWOT Analysis.
  • The Report includes detailed historical and forecasted epidemiology of Cutaneous Squamous Cell Carcinoma (cSCC) in the 7MM (till 2025). According to research, the incident cases of Cutaneous Squamous Cell Carcinoma are expected to reach up to 871,530 by the end of 2025 at a CAGR of XX% for the forecast period i.e., 2015-2025. High incident cases were observed in United States as compared to EU5 and Japan.
  • The Report also covers the therapeutics market revenue, treatment practice/algorithm and detailed market size forecast of Cutaneous Squamous Cell Carcinoma from 2017 to 2025 segmented by seven major markets. United States contributes the major share of Cutaneous Squamous Cell Carcinoma market as compared to EU5 countries and Japan.
  • Market is driven by the use of chemotherapy such as Cisplatin , 5-Fluorouracil (5-FU), and Bleomycin, antibodies such as Cetuximab for the treatment of Cutaneous Squamous Cell Carcinoma.
  • The therapeutic market of Cutaneous Squamous Cell Carcinoma in 7MM is expected to reach USD XXX Million in 2025 at the CAGR of 5.5% for the forecast period i.e., 2015-2025.
Key Coverage and Benefits:
  • Overview of the Global pipeline scenario for Cutaneous Squamous Cell Carcinoma, products and associated companies information
  • Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities
  • The report will help in developing business strategies by understanding the trends shaping and driving the global Cutaneous Squamous Cell Carcinoma (cSCC) market.
  • Organize sales and marketing efforts by identifying the best opportunities for Cutaneous Squamous Cell Carcinoma (cSCC) in US, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
  • The report provides historical as well as forecasted epidemiology of Cutaneous Squamous Cell Carcinoma (cSCC) in the 7MM covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025.
  • To understand the future market competition in the global Cutaneous Squamous Cell Carcinoma (cSCC) market and Insightful review of the key market drivers and barriers.
  • To understand the regulatory scenario in major markets.
  • The Report also covers the detailed global historical and forecasted Cutaneous Squamous Cell Carcinoma (cSCC) market covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan from 2015-2025.
Note: Delivery of this report takes up to 24 hours after purchase.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
  1. Report Introduction
    Table of Contents
  2. Market Overview at a Glance
  3. Total Market Share Distribution of Cutaneous Squamous Cell Carcinoma for 7MM in 2016
  4. Total Market Share Distribution of Cutaneous Squamous Cell Carcinoma for 7MM in 2025
  5. Introduction
  6. Signs and Symptoms
  7. Pathophysiology
  8. Sub-types of cSCC
  9. Risk Factors
  10. Staging of cSCC
  11. Diagnosis
  12. Epidemiology and Patient Population
  13. Total number of Incident cases - Region Wise - (2016 & 2025)
  14. Total number of Incident cases - 7MM Countries - (2016 & 2025)
  15. United States
  16. Germany
  17. France
  18. United Kingdom
  19. Spain
  20. Italy
  21. Japan
  22. Treatment Algorithm
  23. United States
  24. NCCN Guidelines
  25. Europe
  26. British Association of dermatology (BAD) Guidelines
  27. French Dermatology Recommendations Association (aRED)
  28. European Dermatology Forum
  29. London Cancer Skin Pathway Board
  30. National Cancer Institute
  31. Unmet Needs
  32. Marketed Drugs
  33. 5-Fluorouracil (5-FU)
  34. MOA
  35. Study
  36. Xeloda
  37. MOA
  38. Study
  39. Cisplatin
  40. MOA
  41. Study
  42. Bleomycin
  43. MOA
  44. Study
  45. Doxorubicin
  46. MOA
  47. Cetuximab
  48. MOA
  49. Study
  50. Gefitinib
  51. MOA
  52. Study
  53. Cutaneous Squamous Cell Carcinoma (cSCC): Country-Wise Market Analysis
  54. 7 Major Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) (2015-2025)
  55. Region-Specific Market Distribution and Comparison
  56. Overview on Cutaneous Squamous Cell Carcinoma (cSCC) (2016)
  57. Overview on Cutaneous Squamous Cell Carcinoma (cSCC) (2025)
  58. Global Cutaneous Squamous Cell Carcinoma (cSCC): Market Analysis
  59. United States Market Size
  60. Europe Market Outlook
  61. Germany Market Size
  62. France Market Size
  63. United Kingdom Market Size
  64. Spain Market Size
  65. Italy Market Size
  66. Japan Market Size
  67. Market Drivers
  68. Market Barriers
  69. Appendix
  70. Report Methodology
  71. Consulting Services
  72. Disclaimer
  73. About Us
List of Tables
Table 1: Staging of Cutaneous Squamous Cell Carcinoma, 2017
Table 2: Total number of Incident cases - Region wise
Table 3: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in United States (2015-2025)
Table 4: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in Germany (2015-2025)
Table 5: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in France (2015-2025)
Table 6: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in United Kingdom (2015-2025)
Table 7: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in Spain (2015-2025)
Table 8: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in Italy (2015-2025)
Table 9: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in Japan (2015-2025)
Table 10: 7 MM Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Table 11: Region specific market distribution and comparison
Table 12: Cutaneous Squamous Cell Carcinoma (cSCC), Market Revenue (2016) as per the 7MM
Table 13: Cutaneous Squamous Cell Carcinoma(cSCC), Market Revenue (2025) as per the 7MM
Table 14: United States Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Table 15: Germany Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Table 16: France Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Table 17: United Kingdom Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Table 18: Spain Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Table 19: Italy Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Table 20: Japan Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)

List of Figures
Figure 1: Pathophysiology of Cutaneous Squamous Cell Carcinoma
Figure 2: Risk Factors of Squamous Cell Skin Carcinoma
Figure 3: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in United States (2015-2025)
Figure 4: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in Germany (2015-2025)
Figure 5: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in France (2015-2025)
Figure 6: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in United Kingdom (2015-2025)
Figure 7: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in Spain (2015-2025)
Figure 8: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in Italy (2015-2025)
Figure 9: Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) in Japan (2015-2025)
Figure 10: Clinical Presentation of Squamous Cell Skin Carcinoma
Figure 11: Primary and Adjuvant therapy for low risk Squamous Cell Carcinoma
Figure 12: Primary and Adjuvant therapy for High risk Squamous Cell Carcinoma
Figure 13: Treatment of Primary Cutaneous Squamous Cell Carcinoma
Figure 14: Treatment of Primary Cutaneous Squamous Cell Carcinoma
Figure 15: Region specific market distribution and comparison
Figure 16: Total 7 Major Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD, Million (2016)
Figure 17: Total 7 Major Market Size of Cutaneous Squamous Cell Carcinoma(cSCC) in USD, Million (2025)
Figure 18: United States Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Figure 19: Germany Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Figure 20: France Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Figure 21: United Kingdom Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Figure 22: Spain Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Figure 23: Italy Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Figure 24: Japan Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in USD Million, (2015-2025)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll